Quick Answer
Most people who stop Ozempic or Mounjaro regain weight within 18 months — 4x faster than conventional dieting — and eventually restart, per ENDO 2026 research. Never stop without a transition plan.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
If you are taking Ozempic, Wegovy, Mounjaro, or a generic semaglutide injection and are thinking about stopping — perhaps because of the cost, side effects, or a feeling that you have lost enough weight — important new research should give you pause before you make that decision. A study presented at ENDO 2026, the world's largest endocrinology conference held in Chicago in June 2026, found that the majority of people who stop GLP-1 medications eventually restart them. The reason, according to multiple studies, is the same in almost every case: weight comes back fast, and metabolic markers deteriorate.
What the ENDO 2026 Research Found
Researchers at Boston University School of Public Health analyzed a large U.S. health claims database covering adults with type 2 diabetes who had started on liraglutide (Victoza), semaglutide (Ozempic), or tirzepatide (Mounjaro). The study, presented by lead author Sainikhil Sontha at ENDO 2026 and reported by ScienceDaily in June 2026, tracked what happened after patients stopped their GLP-1 medication. The core finding was clear: most people who discontinue GLP-1 drugs eventually come back to treatment.
The reason for returning is well-documented in parallel research. A major meta-analysis published in the British Medical Journal in January 2026, reviewed by the Washington Post, found that people who stop GLP-1 medications regain lost weight approximately four times faster than those who stopped conventional diet-and-exercise programs. Former GLP-1 users were projected to return to their original weight within roughly 18 months of stopping — often much sooner. A Cleveland Clinic study published in March 2026 found that among patients who stopped semaglutide or tirzepatide for obesity, 55 percent gained weight within the first year of stopping.
Why Weight Comes Back After Stopping GLP-1 Drugs
This is not a willpower problem. It is biology. GLP-1 drugs work by acting on receptors in the brain that control hunger and satiety, slowing the stomach from emptying too quickly, and reducing the drive to overeat. When you stop taking the medication, your brain and gut return to their previous state. The hunger signals that were being suppressed come back. Appetite increases. The biological drive to regain the lost weight kicks in — and it can be powerful.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
For people with obesity or type 2 diabetes, the brain's appetite-regulation system is often dysregulated in a way that does not simply correct itself with weight loss alone. GLP-1 drugs compensate for this dysregulation while you are taking them. But the underlying biology has not changed when you stop. This is why researchers and physicians increasingly speak about GLP-1 treatment the same way they speak about blood pressure medication or cholesterol-lowering statins — as a long-term management strategy rather than a short course of treatment.
A companion ENDO 2026 study, also reported by ScienceDaily, found another complicating factor: people who lost weight on GLP-1 drugs actually became less physically active during treatment. This means that when medication stops, patients may be returning to their old weight without having built the habits of exercise and movement that are needed to maintain weight independently. This makes the case even stronger for not treating GLP-1 treatment as a temporary fix.
What This Means for Indian Patients
For Indian patients, this research carries particular weight for two reasons. First, India has an enormous diabetes and obesity burden — approximately 77 million people with type 2 diabetes, and a rapidly growing population of adults with obesity, particularly in urban areas. South Asian bodies are known to develop metabolic disease at lower body weights than Western populations, which means the health stakes of weight regain are especially high for Indian patients. Regaining even a few kilograms can push blood sugar, cholesterol, and blood pressure back out of control.
Second, cost has historically been a major reason Indian patients stop GLP-1 treatment. Ozempic at full price can cost between Rs 5,600 and Rs 9,000 per month, which is out of reach for many families. However, that calculation changed dramatically in March 2026 when the Indian patent on semaglutide expired. Generic versions are now available in India starting at approximately Rs 1,290 per month from companies like Natco Pharma. Dr Reddy's Obeda is available at Rs 4,200 per month. For many patients who previously stopped because of cost, these generics represent an affordable path to staying on treatment.
If you stopped GLP-1 treatment in the past because you could not afford it, it is worth speaking to a specialist again — the pricing landscape has changed significantly.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
What You Should Do Before Stopping GLP-1 Treatment
If you are currently on semaglutide, tirzepatide, or any GLP-1 medication and are considering stopping, the most important thing is to talk to your doctor before making that decision. Do not stop abruptly. Your physician may recommend several options depending on your situation. These include switching to a lower, more affordable maintenance dose rather than stopping entirely; transitioning to a generic semaglutide option to reduce costs while staying protected; adding a structured exercise and dietary program during treatment to build habits that support weight maintenance; or, in some cases, exploring whether bariatric surgery or another intervention might provide more durable results if GLP-1 medications are not sustainable long-term.
The Cleveland Clinic data showed that patients who transitioned to another evidence-based treatment after stopping had significantly better weight outcomes than those who simply stopped with no plan. The worst outcomes were in patients who stopped cold without any transition strategy.
GLP-1 treatment is increasingly recognized as a long-term commitment for people with obesity and type 2 diabetes — similar to the way we manage hypertension or high cholesterol. The medications are remarkably effective while you are taking them. Stopping without a plan is the most common reason that effectiveness is lost.
Call MySurgery at 8588967050 or WhatsApp us to speak with a GLP-1 specialist. Free consultation, callback in 30 minutes.
Disclaimer: This article is based on information published on the referenced websites below and is intended for general awareness only. It is not a substitute for professional medical advice.
References: 1. Medical Daily (ENDO 2026 stop-restart study) — https://www.medicaldaily.com/glp1-ozempic-stop-restart-endo-2026-sciencedaily-weight-regain-study-475779 2. ScienceDaily (ENDO 2026 research) — https://www.sciencedaily.com/releases/2026/06/260615033838.htm 3. Cleveland Clinic (real-world discontinuation study, March 2026) — https://newsroom.clevelandclinic.org/2026/03/12/what-happens-when-patients-stop-taking-glp-1-drugs-new-cleveland-clinic-study-reveals-real-world-insights
MySurgery GLP-1 Team
GLP-1 Research & Patient Education
Have questions about GLP-1 Therapy?
Free consultation. Expert doctors. Callback in 30 minutes.